Abstract
Mitochondrial disorders represent a rare category of diseases that arise from abnormalities in essential proteins necessary for the proper functioning and maintenance of mitochondria. These mutations disrupt the proteins and activities associated with mitochondria, resulting in impairments across various systems and organs in the body, leading to debilitating diseases. They are multisystemic in nature and contain mutations in both the nuclear and mitochondrial genomes. Hence, it is highly challenging to detect mitochondrial illnesses, which makes treating them very challenging. In recent times, the growing emphasis on research and clinical trials in the field of mitochondrial diseases has significantly advanced the current understanding of treatment options for these conditions. As a precision medicine approach, gene therapy has become a potential treatment for mitochondrial illnesses. As therapy is still in its early stages, further research is needed to determine its effectiveness and safety. This chapter explores the biology of the mitochondria, mutations, and prospective uses of gene therapy in the future to treat rare mitochondrial diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alpers BJ (1931) Diffuse progressive degeneration of the gray matter of the cerebrum. Arch Neurol Psychiatr 25:469–505. https://doi.org/10.1001/archneurpsyc.1931.02230030027002
Alston CL, Rocha MC, Lax NZ et al (2017) The genetics and pathology of mitochondrial disease. J Pathol 241:236–250
Angelova PR (2021) Sources and triggers of oxidative damage in neurodegeneration. Free Radic Biol Med 173:52–63. https://doi.org/10.1016/j.freeradbiomed.2021.07.003
Anonymous (2019) Voyager’s CNS gene therapy. Nat Biotechnol 37:204
Anonymous (2023) Mitochondrial diseases: causes, symptoms, diagnosis & treatment
Artika IM (2020) Allotopic expression of mitochondrial genes: basic strategy and progress. Genes Dis 7:578–584
Bacman SR, Williams SL, Pinto M et al (2013) Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 19:1111–1113. https://doi.org/10.1038/nm.3261
Baertling F, Rodenburg RJ, Schaper J et al (2014) A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry 85:257–265
Bahr T, Welburn K, Donnelly J, Bai Y (2020) Emerging model systems and treatment approaches for Leber’s hereditary optic neuropathy: challenges and opportunities. Biochim Biophys Acta Mol basis Dis 1866:165743. https://doi.org/10.1016/j.bbadis.2020.165743
Belbellaa B, Reutenauer L, Messaddeq N et al (2020) High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol Ther Methods Clin Dev 19:120–138. https://doi.org/10.1016/j.omtm.2020.08.018
Boominathan A, Vanhoozer S, Basisty N et al (2016) Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA complex V null mutant. Nucleic Acids Res gkw756. https://doi.org/10.1093/nar/gkw756
Borenfreund E, Bendich A (1961) A study of the penetration of mammalian cells by deoxyribonucleic acids. J Cell Biol 9:81–91. https://doi.org/10.1083/jcb.9.1.81
Brown G (2014) Defects of thiamine transport and metabolism. J Inherit Metab Dis 37(4):577–585
Brown WM, George M, Wilson AC (1979) Rapid evolution of animal mitochondrial DNA. Proc Natl Acad Sci 76:1967–1971. https://doi.org/10.1073/pnas.76.4.1967
Bua E, Johnson J, Herbst A et al (2006) Mitochondrial DNA–deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 79:469–480. https://doi.org/10.1086/507132
Bugiardini E, Pope S, Feichtinger RG et al (2019) Utility of whole blood thiamine pyrophosphate evaluation in TPK1-related diseases. J Clin Med 8:991. https://doi.org/10.3390/jcm8070991
Calvo SE, Mootha VK (2010) The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet 11:25–44. https://doi.org/10.1146/annurev-genom-082509-141720
Calvo SE, Clauser KR, Mootha VK (2016) MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res 44:D1251–D1257. https://doi.org/10.1093/nar/gkv1003
Campuzano V, Montermini L, Molto MD et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254):1423–1427
Carroll D (2011) Genome engineering with zinc-finger nucleases. Genetics 188:773–782. https://doi.org/10.1534/genetics.111.131433
Carroll CJ, Brilhante V, Suomalainen A (2014) Next-generation sequencing for mitochondrial disorders. Br J Pharmacol 171:1837–1853
Chan SSL, Longley MJ, Naviaux RK, Copeland WC (2005) Mono-allelic POLG expression resulting from nonsense-mediated decay and alternative splicing in a patient with Alpers syndrome. DNA Repair 4(12):1381–1389
Chan SSL, Longley MJ, Copeland WC (2006) Modulation of the W748S mutation in DNA polymerase γ by the E1143G polymorphism in mitochondrial disorders. Hum Mol Genet 15:3473–3483. https://doi.org/10.1093/hmg/ddl424
Chinnery PF (2015) Mitochondrial disease in adults: what’s old and what’s new? EMBO Mol Med 7:1503–1512. https://doi.org/10.15252/emmm.201505079
Chinnery PF, Hudson G (2013) Mitochondrial genetics. Br Med Bull 106:135–159
Cook A, Giunti P (2017) Friedreich’s ataxia: clinical features, pathogenesis and management. Br Med Bull 124:19–30
Copeland WC, Longley MJ (2003) DNA polymerase gamma in mitochondrial DNA replication and repair. ScientificWorldJournal 3:34–44
Cossée M, Schmitt M, Campuzano V et al (1997) Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci 94:7452–7457. https://doi.org/10.1073/pnas.94.14.7452
Davidzon G, Mancuso M, Ferraris S et al (2005) POLG mutations and Alpers syndrome. Ann Neurol 57:921–923. https://doi.org/10.1002/ana.20498
Delatycki MB, Bidichandani SI (2019) Friedreich ataxia—pathogenesis and implications for therapies. Neurobiol Dis 132:104606
Deverman BE, Pravdo PL, Simpson BP et al (2016) Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34:204–209. https://doi.org/10.1038/nbt.3440
Di Donfrancesco A, Massaro G, Di Meo I et al (2022) Gene therapy for mitochondrial diseases: current status and future perspective. Pharmaceutics 14:1287
Di Meo I, Marchet S, Lamperti C et al (2017) AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome. Gene Ther 24:661–667. https://doi.org/10.1038/gt.2017.53
DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348:2656–2668. https://doi.org/10.1056/nejmra022567
Distelmaier F, Haack TB, Wortmann SB et al (2017) Treatable mitochondrial diseases: cofactor metabolism and beyond. Brain 140:e11
Duchen MR (2000) Mitochondria and calcium: from cell signalling to cell death. J Physiol 529:57–68. https://doi.org/10.1111/j.1469-7793.2000.00057.x
El-Hattab AW, Adesina AM, Jones J, Scaglia F (2015) MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 116:4–12
Elizabeth Hunter Szybalska B, Szybalski W (1908) GENETICS OF HUMAN CELL LINES, IV. DNA-MEDIATED HERITABLE TRANSFORMATION OF A BIOCHEMICAL TRAIT
Fernandez-Vizarra E, Zeviani M, Zeviani M (2021) Mitochondrial disorders of the OXPHOS system. FEBS Lett 595:1062–1106. https://doi.org/10.1002/1873-3468.13995
Ferrari G, Lamantea E, Donati A et al (2005) Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA. Brain 128:723–731. https://doi.org/10.1093/brain/awh410
Finsterer J, Zarrouk Mahjoub S (2012) Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 8:71–79. https://doi.org/10.1517/17425255.2012.644535
Fogleman S, Santana C, Bishop C, et al (2016) CRISPR/Cas9 and mitochondrial gene replacement therapy: promising techniques and ethical considerations
Gaj T, Gersbach CA, Barbas CF (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397–405. https://doi.org/10.1016/j.tibtech.2013.04.004
Ganetzky RD, Stendel C, McCormick EM et al (2019) MT-ATP6 mitochondrial disease variants: phenotypic and biochemical features analysis in 218 published cases and cohort of 14 new cases. Hum Mutat 40:499–515
Gerards M, Sallevelt SCEH, Smeets HJM (2016) Leigh syndrome: resolving the clinical and genetic heterogeneity paves the way for treatment options. Mol Genet Metab 117:300–312
Giles RE, Blanc H, Cann HM, Wallace DC (1980) Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci 77:6715–6719. https://doi.org/10.1073/pnas.77.11.6715
Gorman GS, Chinnery PF, DiMauro S et al (2016) Mitochondrial diseases. Nat Rev Dis Primers 2:16080. https://doi.org/10.1038/nrdp.2016.80
Greaves LC, Reeve AK, Taylor RW, Turnbull DM (2012) Mitochondrial DNA and disease. J Pathol 226:274–286
Hanaford AR, Cho YJ, Nakai H (2022) AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives. Orphanet J Rare Dis 17:217
Harding BN, Alsanjari N, Smith SJM et al (1995) Progressive neuronal degeneration of childhood with liver disease (Alpers’ disease) presenting in young adults. J Neurol Neurosurg Psychiatry 58:320–325. https://doi.org/10.1136/jnnp.58.3.320
Hayashi G, Cortopassi G (2015) Oxidative stress in inherited mitochondrial diseases. Free Radic Biol Med 88:10–17
Herbert M, Turnbull D (2018) Progress in mitochondrial replacement therapies. Nat Rev Mol Cell Biol 19:71–72
Hirano M, Pavlakis SG (1994) Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol 9:4–13
Hirano M, Emmanuele V, Quinzii CM (2018) Emerging therapies for mitochondrial diseases. Essays Biochem 62:467–481
Horvath R, Hudson G, Ferrari G et al (2006) Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. Brain 129:1674–1684. https://doi.org/10.1093/brain/awl088
Hussain SRA, Yalvac ME, Khoo B et al (2021) Adapting CRISPR/Cas9 system for targeting mitochondrial genome. Front Genet 12:627050. https://doi.org/10.3389/fgene.2021.627050
Ikeda T, Osaka H, Shimbo H et al (2018) Mitochondrial DNA 3243A>T mutation in a patient with MELAS syndrome. Hum Genome Var 5:25. https://doi.org/10.1038/s41439-018-0026-6
Incecik F, Herguner O, Besen S et al (2018) Late-onset Leigh syndrome due to NDUFV1 mutation in a 10-year-old boy initially presenting with ataxia. J Pediatr Neurosci 13:205–207. https://doi.org/10.4103/jpn.jpn_138_17
Isnard R, Kalotka H, Dürr A et al (1997) Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich’s ataxia. Circulation 95:2247–2249. https://doi.org/10.1161/01.CIR.95.9.2247
Kang E, Wu J, Gutierrez NM et al (2016) Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. Nature 540:270–275. https://doi.org/10.1038/nature20592
Karaarslan C (2019) Leber’s hereditary optic neuropathy as a promising disease for gene therapy development. Adv Ther 36:3299–3307
Kirches E (2011) LHON: mitochondrial mutations and more
Koeppen AH (2011) Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 303:1–12
Kremer LS, Wortmann SB, Prokisch H (2018) “Transcriptomics”: molecular diagnosis of inborn errors of metabolism via RNA-sequencing. J Inherit Metab Dis 41:525–532. https://doi.org/10.1007/s10545-017-0133-4
Lake NJ, Bird MJ, Isohanni P, Paetau A (2015) Leigh syndrome. J Neuropathol Exp Neurol 74:482–492. https://doi.org/10.1097/NEN.0000000000000195
Lane N (2011) Mitonuclear match: optimizing fitness and fertility over generations drives ageing within generations. BioEssays 33:860–869. https://doi.org/10.1002/bies.201100051
Lawless C, Greaves L, Reeve AK et al (2020) The rise and rise of mitochondrial DNA mutations. Open Biol 10:200061
Lax NZ, Turnbull DM, Reeve AK (2011) Mitochondrial mutations: newly discovered players in neuronal degeneration. Neuroscientist 17:645–658. https://doi.org/10.1177/1073858411385469
LEIGH D (1951) Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 14:216–221. https://doi.org/10.1136/jnnp.14.3.216
Li C, Samulski RJ (2020) Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 21:255–272
Li H, Yang Y, Hong W et al (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther 5:1
Lim SE, Longley MJ, Copeland WC (1999) The mitochondrial p55 accessory subunit of human DNA polymerase γ enhances DNA binding, promotes Processive DNA synthesis, and confers N-ethylmaleimide resistance. J Biol Chem 274:38197–38203. https://doi.org/10.1074/jbc.274.53.38197
Lou X, Shi H, Wen S et al (2018) A novel NDUFS3 mutation in a Chinese patient with severe Leigh syndrome. J Hum Genet 63:1269–1272. https://doi.org/10.1038/s10038-018-0505-0
Lyseng-Williamson KA (2016) Idebenone: a review in Leber’s hereditary optic neuropathy. Drugs 76:805–813. https://doi.org/10.1007/s40265-016-0574-3
Manfredi G, Fu J, Ojaimi J et al (2002) Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet 30:394–399. https://doi.org/10.1038/ng851
McFarland R, Chinnery PF, Blakely EL et al (2007) Homoplasmy, heteroplasmy, and mitochondrial dystonia. Neurology 69:911–916. https://doi.org/10.1212/01.wnl.0000267843.10977.4a
Nakai H, Yant SR, Storm TA et al (2001) Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75:6969–6976. https://doi.org/10.1128/jvi.75.15.6969-6976.2001
Nass MM (1966) The circularity of mitochondrial DNA. Proc Natl Acad Sci 56:1215–1222. https://doi.org/10.1073/pnas.56.4.1215
Naviaux RK, Nguyen KV (2004) POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol 55:706–712. https://doi.org/10.1002/ana.20079
Naviaux RK, Nyhan WL, Barshop BA et al (1999) Mitochondrial DNA polymerase γ deficiency and mtDNA depletion in a child with Alpers’ syndrome. Ann Neurol 45:54–58
Nesbitt V, Alston CL, Blakely EL et al (2014) A national perspective on prenatal testing for mitochondrial disease. Eur J Hum Genet 22:1255–1259. https://doi.org/10.1038/ejhg.2014.35
Nguyen KV, Østergaard E, Holst Ravn S et al (2005) POLG mutations in Alpers syndrome. Neurology 65:1493–1495. https://doi.org/10.1212/01.wnl.0000182814.55361.70
Nia Monró E, Moltó MD, Martínez F et al (1997) (1997) Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet. 61(1):101–110
Nogueira C, Carrozzo R, Vilarinho L, Santorelli FM (2011) Infantile-onset disorders of mitochondrial replication and protein synthesis. J Child Neurol 26:866–875
Oca-Cossio J, Kenyon L, Hao H, Moraes CT (2003) Limitations of Allotopic expression of mitochondrial genes in mammalian cells. Genetics 165:707–720. https://doi.org/10.1093/genetics/165.2.707
Ochman H, Moran NA (2001) Genes lost and genes found: evolution of bacterial pathogenesis and Symbiosis. Science (1979) 292:1096–1099. https://doi.org/10.1126/science.1058543
Ortigoza-Escobar JD, Molero-Luis M, Arias A et al (2016) Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome. Brain 139:31–38. https://doi.org/10.1093/brain/awv342
Perdomini M, Belbellaa B, Monassier L et al (2014) Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med 20:542–547. https://doi.org/10.1038/nm.3510
Pereira CV, Peralta S, Arguello T et al (2020) Myopathy reversion in mice after restauration of mitochondrial complex I. EMBO Mol Med 12:e10674. https://doi.org/10.15252/emmm.201910674
Piguet F, de Montigny C, Vaucamps N et al (2018) Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol Ther 26:1940–1952. https://doi.org/10.1016/j.ymthe.2018.05.006
Puccio H, Koenig M (2002) Friedreich ataxia: a paradigm for mitochondrial diseases. Curr Opin Genet Dev 12(3):272–277
Rahman J, Noronha A, Thiele I, Rahman S (2017) Leigh map: a novel computational diagnostic resource for mitochondrial disease. Ann Neurol 81:9–16. https://doi.org/10.1002/ana.24835
Riordan-Eva P, Sanders MD, Govan GG et al (1995) The clinical features of Leber’s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 118:319–337. https://doi.org/10.1093/brain/118.2.319
Rooney JP, Ryde IT, Sanders LH et al (2015) PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol 1241:23–38
Rossignol R, Faustin B, Rocher C et al (2003) Mitochondrial threshold effects. Biochem J 370:751–762. https://doi.org/10.1042/bj20021594
Russell OM, Gorman GS, Lightowlers RN, Turnbull DM (2020) Mitochondrial diseases: hope for the future. Cell 181:168–188. https://doi.org/10.1016/j.cell.2020.02.051
Sahel J-A, Newman NJ, Yu-Wai-Man P et al (2021) Gene therapies for the treatment of Leber hereditary optic neuropathy. Int Ophthalmol Clin 61(4):195–208
Samuels DC, Wonnapinij P, Chinnery PF (2013) Preventing the transmission of pathogenic mitochondrial DNA mutations: can we achieve long-term benefits from germ-line gene transfer? Hum Reprod 28:554–559. https://doi.org/10.1093/humrep/des439
Sandbank U, Lerman P (1972) Progressive cerebral poliodystrophy—Alpers’ disease. Disorganized giant neuronal mitochondria on electron microscopy. J Neurol Neurosurg Psychiatry 35:749–755. https://doi.org/10.1136/jnnp.35.6.749
Saneto RP, Naviaux RK (2010) Polymerase gamma disease through the ages. Dev Disabil Res Rev 16:163–174
Sato M, Sato K (2012) Maternal inheritance of mitochondrial DNA. Autophagy 8:424–425. https://doi.org/10.4161/auto.19243
Silva AM, Brown JM, Buckle VJ et al (2015) Expanded GAA repeats impair FXN gene expression and reposition the FXN locus to the nuclear lamina in single cells. Hum Mol Genet 24:3457–3471. https://doi.org/10.1093/hmg/ddv096
Slone J, Huang T (2020) The special considerations of gene therapy for mitochondrial diseases. NPJ Genom Med 5:7
Soldatov VO, Kubekina MV, Skorkina MY et al (2022) Current advances in gene therapy of mitochondrial diseases. J Transl Med 20:562
Spangenberg L, Graña M, Greif G et al (2016) 3697G>A in MT-ND1 is a causative mutation in mitochondrial disease. Mitochondrion 28:54–59. https://doi.org/10.1016/j.mito.2016.03.006
Stefano GB, Kream RM (2016) Mitochondrial DNA heteroplasmy in human health and disease. Biomed Rep 4:259–262. https://doi.org/10.3892/br.2016.590
Stenton SL, Prokisch H (2020) Genetics of mitochondrial diseases: identifying mutations to help diagnosis. EBioMedicine 56:102784. https://doi.org/10.1016/j.ebiom.2020.102784
Stewart JD, Horvath R, Baruffini E et al (2010) Polymerase γGene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52:1791–1796. https://doi.org/10.1002/hep.23891
Tachibana M, Sparman M, Sritanaudomchai H et al (2009) Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 461:367–372. https://doi.org/10.1038/nature08368
Tachibana M, Amato P, Sparman M et al (2013) Towards germline gene therapy of inherited mitochondrial diseases. Nature 493:627–631. https://doi.org/10.1038/nature11647
Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6:389–402. https://doi.org/10.1038/nrg1606
Thorburn DR (2000) Practical problems in detecting abnormal mitochondrial function and genomes. Hum Reprod 15:57–67. https://doi.org/10.1093/humrep/15.suppl_2.57
Tinker RJ, Lim AZ, Stefanetti RJ, McFarland R (2021) Current and emerging clinical treatment in mitochondrial disease. Mol Diagn Ther 25:181–206
Tsou AY, Paulsen EK, Lagedrost SJ et al (2011) Mortality in Friedreich ataxia. J Neurol Sci 307:46–49. https://doi.org/10.1016/j.jns.2011.05.023
Tuppen HAL, Blakely EL, Turnbull DM, Taylor RW (2010) Mitochondrial DNA mutations and human disease. Biochim Biophys Acta Bioenerg 1797:113–128
Tzoulis C, Engelsen BA, Telstad W et al (2006) The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 129:1685–1692. https://doi.org/10.1093/brain/awl097
Wallace DC, Chalkia D (2013) Mitochondrial DNA genetics and the Heteroplasmy conundrum in evolution and disease. Cold Spring Harb Perspect Biol 5:a021220–a021220. https://doi.org/10.1101/cshperspect.a021220
White SL, Collins VR, Wolfe R et al (1999) Genetic counseling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993. Am J Hum Genet 65:474–482. https://doi.org/10.1086/302488
Wiltshire E, Davidzon G, Dimauro S et al (2008) Juvenile Alpers disease. Arch Neurol 65:121–124. https://doi.org/10.1001/archneurol.2007.14
Wolf DP, Mitalipov N, Mitalipov S (2015) Mitochondrial replacement therapy in reproductive medicine. Trends Mol Med 21:68–76
Yamanaka H, Gatanaga H, Kosalaraksa P et al (2007) Novel mutation of human DNA polymerase γ associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 195:1419–1425. https://doi.org/10.1086/513872
Yang S, Ma S, Wan X et al (2016) Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy. EBioMedicine 10:258–268. https://doi.org/10.1016/j.ebiom.2016.07.002
Yu H, Porciatti V, Lewin A et al (2018) Longterm reversal of severe visual loss by mitochondrial gene transfer in a mouse model of Leber hereditary optic neuropathy. Sci Rep 8:5587. https://doi.org/10.1038/s41598-018-23836-y
Yu-Wai-Man P, Newman NJ, Carelli V et al (2020) Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med 12:eaaz7423. https://doi.org/10.1126/scitranslmed.aaz7423
Zhang H, Burr SP, Chinnery PF (2018) The mitochondrial DNA genetic bottleneck: inheritance and beyond. Essays Biochem 62:225–234
Zullo SJ (2001) Gene therapy of mitochondrial DNA mutations: a brief, biased history of allotopic expression in mammalian cells. Semin Neurol 21(3):327–335
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Tirunagari, S., Dsa, S., Jayaraman, M. (2024). Current Insights into the Potential of Gene Therapy to Treat Rare Mitochondrial Diseases. In: Umair, M., Rafeeq, M., Alam, Q. (eds) Rare Genetic Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-99-9323-9_8
Download citation
DOI: https://doi.org/10.1007/978-981-99-9323-9_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-9322-2
Online ISBN: 978-981-99-9323-9
eBook Packages: MedicineMedicine (R0)